If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL), now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech is undeniably ascendant after getting its first medicine ...
motleyfoolusx:llyusx:mdgl
Madrigal Pharmaceuticals (NASDAQ: MDGL) is in a position that most other biotechs envy. Its first medicine just hit the market, sales are due to start rolling in, and there aren't any other companies that can slow it down -- for now, that is. By mid-2027, its shareholders will probably be richer than ...
motleyfoolusx:mdgl
Viking Therapeutics (NASDAQ: VKTX) and Madrigal Pharmaceuticals (NASDAQ: MDGL) are highly prominent biotech companies that have a lot in common. Both focus on treating metabolic illnesses like liver disease and obesity, and, until recently, despite their promising pipeline programs, both were lacking ...
motleyfoolusx:vktxusx:mdgl
Madrigal Pharmaceuticals' (NASDAQ: MDGL) shares are down by 27% over the past year, while the S&P 500 is up by 26%. However, this poor performance hardly reflects the progress the biotech has made. Madrigal recently earned regulatory approval for Rezdiffra, a therapy for non-alcoholic steatohepatitis ...
motleyfoolusx:mdgl
